An obesity-care startup steering employers toward cost-effective GLP-1 coverage. A $15 million Series A led by Cornucopian Capital as employers trim drug benefits.
An obesity-care startup steering employers toward cost-effective GLP-1 coverage. A $15 million Series A led by Cornucopian Capital as employers trim drug benefits.